Estrogen therapy in postmenopausal osteoporosis what we know and what we don't

被引:0
|
作者
Roux, C [1 ]
机构
[1] COCHIN TEACHING HOSP,BONE DIS RES CTR,PARIS,FRANCE
来源
REVUE DU RHUMATISME | 1997年 / 64卷 / 06期
关键词
estrogen; osteoporosis; menopause; densitometry;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Replacement estrogen therapy is of proven efficacy for the prevention and treatment of postmenopausal bone loss, Oral and transdermal 17 beta estradiol have provided similar benefits in clinical studies, The lowest effective doses are 0.625 mg per day for conjugated estrogens, 2 mg per day for oral 17 beta estradiol 1.5 mu g per day for 17 beta estradiol gel, and 50-mu g 17 beta estradiol patch per day. Bone mineral density should be monitored if lower doses are used, Several epidemiologic studies found that a decrease in the incidence of osteoporotic fractures was achieved only when the duration of estrogen replacement therapy exceeded seven years, It follows that replacement therapy should be started at cessation of menses, if possible, However delayed replacement therapy (i.e., at 65 years of age) is unquestionably effective.
引用
收藏
页码:402 / 409
页数:8
相关论文
共 50 条
  • [1] Menopause and cardiometabolic diseases: What we (don't) know and why it matters
    Roa-Diaz, Zayne M.
    Raguindin, Peter Francis
    Bano, Arjola
    Laine, Jessica E.
    Muka, Taulant
    Glisic, Marija
    MATURITAS, 2021, 152 : 48 - 56
  • [2] MENOPAUSAL HORMONE THERAPY: WHAT WE KNOW NOW
    Roush, Karen
    AMERICAN JOURNAL OF NURSING, 2011, 111 (06) : 38 - 47
  • [3] Androgen therapy in women: What we think we know
    Drillich, Ann
    Davis, Susan R.
    EXPERIMENTAL GERONTOLOGY, 2007, 42 (06) : 457 - 462
  • [4] Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?
    Abdulameer, Shaymaa Abdalwahed
    Sulaiman, Syed Azhar Syed
    Hassali, Mohamed Azmi Ahmad
    Subramaniam, Karuppiah
    Sahib, Mohanad Naji
    PATIENT PREFERENCE AND ADHERENCE, 2012, 6 : 435 - 448
  • [5] Vaginal Aging-What We Know and What We Do Not Know
    Szymanski, Jacek K.
    Slabuszewska-Jozwiak, Aneta
    Jakiel, Grzegorz
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (09)
  • [6] Hormones and dry eye syndrome: an update on what we do and don't know
    Rocha, Eduardo Melani
    Mantelli, Flavio
    Nominato, Luis Fernando
    Bonini, Stefano
    CURRENT OPINION IN OPHTHALMOLOGY, 2013, 24 (04) : 348 - 355
  • [7] What do we know about spinal manual therapy for people with osteoporosis? A narrative review
    McArthur, Caitlin
    Ziebart, Christina
    Laprade, Judi
    PHYSICAL THERAPY REVIEWS, 2021, 26 (01) : 42 - 52
  • [8] Estrogen Formation and Inactivation Following TBI: What we Know and Where we Could go
    Duncan, Kelli A.
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [9] Abnormal bleeding in postmenopausal hormone users-What do we know today?
    Hickey, Martha
    Ambekar, Manju
    MATURITAS, 2009, 63 (01) : 45 - 50
  • [10] Denosumab in postmenopausal osteoporosis: what the clinician needs to know
    Lewiecki, E. Michael
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2009, 1 (01) : 13 - 26